Molecular and Genetic Bases of Inhibition of Tick-Borne Encephalitis Virus Replication by Eprosartan and Ribavirin

Леонова, Г Н; Maistrovskaya, O S; Lubova, V. A.

doi:10.1007/s10517-020-05003-4

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ribavirin significantly inhibited the proliferation of the highly virulent strain of the TBEV in the PK cell cultures (Krylova and Leonova, 2016). A recent study also reported that ribavirin exhibited inhibition toward highly and low-virulent strains of TBEV on SPEV cells (Leonova et al, 2020). However, 50 μM of ribavirin displayed no noticeable inhibitory effects on reducing TBEV titers in rat organotypic cerebellum slices (Lenz et al, 2018).…”

Section: Discussionmentioning

confidence: 94%

Inhibition of tick-borne encephalitis virus in cell cultures by ribavirin

Tang¹,

Tang²,

Peng³

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

Tick-borne encephalitis virus (TBEV) belonging to arboviruses is a major member of zoonotic pathogens. TBEV infection causes severe human encephalitis without specific antiviral drugs. Due to its use of antiviral drug against a wide range of viruses, we investigated antiviral effect of ribavirin against TBEV in susceptible human cell lines A549 and SH-SY5Y. Ribavirin displayed minor cytotoxicity on multiple cell lines. Ribavirin obviously impaired TBEV replication and protected the infected cells from cytopathic effect. Importantly, ribavirin markedly inhibited TBEV propagation, as evidenced by impairment of TBEV production and viral RNA replication. Treatment with ribavirin (co-treatment and post-treatment) led to a dose-dependent reduction in TBEV titers as well as the viral RNA levels. Antiviral protein myxovirus resistance A mRNA expression was significantly up-regulated and signal transducer and activator of transcription 3 was activated in TBEV-infected A549 cells upon the ribavirin treatment. Induction of inflammatory cytokine tumor necrosis factor alpha by TBEV was decreased in A549 cells with the treatment of ribavirin, whereas interleukin 1 beta release appeared to be unaffected. These results suggest that ribavirin might represent a promising safe and effective antiviral drug against TBEV.

show abstract

Section: Discussionmentioning

confidence: 94%